A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS).
Saved in:
| Title: | A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). |
|---|---|
| Authors: | Ostermann, Marlies1 (AUTHOR), Corteville, David C.2 (AUTHOR), Doi, Kent3 (AUTHOR), Koyner, Jay L.4 (AUTHOR), Lamy, Andre5 (AUTHOR), Li, Gerry6 (AUTHOR), Solinsky, Christine M.6 (AUTHOR) christine.solinsky@alexion.com, Winterberg, Pamela D.6,7 (AUTHOR), Smith, William T.6,8 (AUTHOR), Mehta, Ravindra L.9 (AUTHOR), Murray, Patrick T.10 (AUTHOR), Shaw, Andrew D.11,12 (AUTHOR), Zarbock, Alexander13 (AUTHOR), Engelman, Daniel T.14 (AUTHOR) |
| Source: | Trials. 5/30/2025, Vol. 26 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17456215 |
|---|---|
| DOI: | 10.1186/s13063-025-08895-7 |
